180 related articles for article (PubMed ID: 30645190)
1. SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma.
Carreno G; Boult JKR; Apps J; Gonzalez-Meljem JM; Haston S; Guiho R; Stache C; Danielson LS; Koers A; Smith LM; Virasami A; Panousopoulos L; Buchfelder M; Jacques TS; Chesler L; Robinson SP; Martinez-Barbera JP
Endocr Relat Cancer; 2019 Mar; 26(3):355-366. PubMed ID: 30645190
[TBL] [Abstract][Full Text] [Related]
2. Adamantinomatous craniopharyngioma: moving toward targeted therapies.
Hengartner AC; Prince E; Vijmasi T; Hankinson TC
Neurosurg Focus; 2020 Jan; 48(1):E7. PubMed ID: 31896087
[TBL] [Abstract][Full Text] [Related]
3. Sonic Hedgehog pathway is upregulated in adamantinomatous craniopharyngiomas.
Gomes DC; Jamra SA; Leal LF; Colli LM; Campanini ML; Oliveira RS; Martinelli CE; Elias PC; Moreira AC; Machado HR; Saggioro F; Neder L; Castro M; Antonini SR
Eur J Endocrinol; 2015 May; 172(5):603-8. PubMed ID: 25693592
[TBL] [Abstract][Full Text] [Related]
4. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.
Apps JR; Carreno G; Gonzalez-Meljem JM; Haston S; Guiho R; Cooper JE; Manshaei S; Jani N; Hölsken A; Pettorini B; Beynon RJ; Simpson DM; Fraser HC; Hong Y; Hallang S; Stone TJ; Virasami A; Donson AM; Jones D; Aquilina K; Spoudeas H; Joshi AR; Grundy R; Storer LCD; Korbonits M; Hilton DA; Tossell K; Thavaraj S; Ungless MA; Gil J; Buslei R; Hankinson T; Hargrave D; Goding C; Andoniadou CL; Brogan P; Jacques TS; Williams HJ; Martinez-Barbera JP
Acta Neuropathol; 2018 May; 135(5):757-777. PubMed ID: 29541918
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma.
Andoniadou CL; Gaston-Massuet C; Reddy R; Schneider RP; Blasco MA; Le Tissier P; Jacques TS; Pevny LH; Dattani MT; Martinez-Barbera JP
Acta Neuropathol; 2012 Aug; 124(2):259-71. PubMed ID: 22349813
[TBL] [Abstract][Full Text] [Related]
6. Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin.
Stache C; Bils C; Fahlbusch R; Flitsch J; Buchfelder M; Stefanits H; Czech T; Gaipl U; Frey B; Buslei R; Hölsken A
Neurosurg Focus; 2016 Dec; 41(6):E14. PubMed ID: 27903123
[TBL] [Abstract][Full Text] [Related]
7. Transcription Factor GLI1 Induces IL-6-Mediated Inflammatory Response and Facilitates the Progression of Adamantinomatous Craniopharyngioma.
Zhao J; Yang Y; Pan Y; Zhou P; Wang J; Zheng Y; Zhang X; Zhai S; Zhang X; Li L; Yang D
ACS Chem Neurosci; 2023 Sep; 14(18):3347-3356. PubMed ID: 37691264
[TBL] [Abstract][Full Text] [Related]
8. Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics.
Robinson LC; Santagata S; Hankinson TC
Neurosurg Focus; 2016 Dec; 41(6):E3. PubMed ID: 27903126
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathology of adamantinomatous craniopharyngioma: review and opportunities for practice.
Apps JR; Martinez-Barbera JP
Neurosurg Focus; 2016 Dec; 41(6):E4. PubMed ID: 27903120
[TBL] [Abstract][Full Text] [Related]
10. Differential Expression of Stem Cell Markers in Human Adamantinomatous Craniopharyngioma and Pituitary Adenoma.
Chang CV; Araujo RV; Cirqueira CS; Cani CM; Matushita H; Cescato VA; Fragoso MC; Bronstein MD; Zerbini MC; Mendonca BB; Carvalho LR
Neuroendocrinology; 2017; 104(2):183-193. PubMed ID: 27161333
[TBL] [Abstract][Full Text] [Related]
11. Identification of targets for rational pharmacological therapy in childhood craniopharyngioma.
Gump JM; Donson AM; Birks DK; Amani VM; Rao KK; Griesinger AM; Kleinschmidt-DeMasters BK; Johnston JM; Anderson RC; Rosenfeld A; Handler M; Gore L; Foreman N; Hankinson TC
Acta Neuropathol Commun; 2015 May; 3():30. PubMed ID: 25990246
[TBL] [Abstract][Full Text] [Related]
12. Adamantinomatous craniopharyngioma: pathology, molecular genetics and mouse models.
Martinez-Barbera JP; Buslei R
J Pediatr Endocrinol Metab; 2015 Jan; 28(1-2):7-17. PubMed ID: 25503464
[TBL] [Abstract][Full Text] [Related]
13. Hedgehog pathway permissive conditions allow generation of immortal cell lines from granule cells derived from cancerous and non-cancerous cerebellum.
Heil C
Open Biol; 2019 Jan; 9(1):180145. PubMed ID: 30958113
[TBL] [Abstract][Full Text] [Related]
14. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
Li Y; Song Q; Day BW
Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
[TBL] [Abstract][Full Text] [Related]
15. Preclinical transgenic and patient-derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngioma.
Boult JKR; Apps JR; Hölsken A; Hutchinson JC; Carreno G; Danielson LS; Smith LM; Bäuerle T; Buslei R; Buchfelder M; Virasami AK; Koers A; Arthurs OJ; Jacques TS; Chesler L; Martinez-Barbera JP; Robinson SP
Brain Pathol; 2018 Jul; 28(4):475-483. PubMed ID: 28481062
[TBL] [Abstract][Full Text] [Related]
16. Interleukin‑6 induces an epithelial‑mesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration.
Zhou J; Zhang C; Pan J; Chen L; Qi ST
Mol Med Rep; 2017 Jun; 15(6):4123-4131. PubMed ID: 28487953
[TBL] [Abstract][Full Text] [Related]
17. CD47 promotes the proliferation and migration of adamantinomatous craniopharyngioma cells by activating the MAPK/ERK pathway, and CD47 blockade facilitates microglia-mediated phagocytosis.
Zhang H; Wang C; Fan J; Zhu Q; Feng Y; Pan J; Peng J; Shi J; Qi S; Liu Y
Neuropathol Appl Neurobiol; 2022 Jun; 48(4):e12795. PubMed ID: 35156226
[TBL] [Abstract][Full Text] [Related]
18. Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma.
Martinez-Barbera JP
Neuropathol Appl Neurobiol; 2015 Oct; 41(6):721-32. PubMed ID: 25611703
[TBL] [Abstract][Full Text] [Related]
19. Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target.
Yang C; Yong L; Liang C; Li Y; Ma Y; Wei F; Jiang L; Zhou H; He G; Pan X; Hai B; Wu J; Xu Y; Liu Z; Liu X
Oncogene; 2020 Jun; 39(24):4711-4727. PubMed ID: 32404987
[TBL] [Abstract][Full Text] [Related]
20. Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer.
Fan C; Wang Y; Liu Z; Sun Y; Wang X; Wei G; Wei J
Int J Mol Med; 2015 Jul; 36(1):204-14. PubMed ID: 25999130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
